tbuckley/cabot-search huggingface dataset:
Conventional and Flowcytometric Minimal Residual Disease Based Risk Stratified Post Remission Therapy Improves Survival in Ph-Negative Pediatric Acute Lymphoblastic Leukemia- Single Centre Experience from South India
Authors: Rema Ganapathy, Aswathy Ashok Beenakumari, Syamaprasad Vinayakumar, Remya Sudevan, Renjitha Bhaskaran, Shivali Ahlawat, Geeta Vidyadharan, Karthika K V, Manoj Unni, Ullas Mony, Neeraj Sidharthan
Journal: Blood (2021)
Abstract 9188: Sex Differences in Cardiovascular Risk and Guideline-Based Preventive Medication Use Among Sudden Death Victims
Authors: Susan Keen, Kaitlin Shartle, Ross J Simpson
Journal: Circulation (2021)

Introduction: Atherosclerotic cardiovascular disease (ASCVD) is associated with an increased risk of sudden death. Preventive medications are recommended by clinical practice guidelines for those with elevated ASCVD risk. Guidelines are often underutilized and use of preventive medications differs by sex. Methods: Out-of-hospital deaths of adults aged 18-64 were reported by emergency medical services in Wake County, North Carolina from 2013-2015 and underwent adjudication to identify sudden unexpected death cases. A cohort of 1,114 living controls was generated through random sampling from a central electronic health records repository and propensity scores matched to the sudden death victims based on sex and race. A 10-year ASCVD risk was calculated for all subjects with the requisite components and categorized as low (&lt;7.5%), intermediate (7.5%-19.9%), and high (≥20%). Use of preventive medications, specifically aspirin and statin, was assessed. Logistic regression models were fitted to evaluate the association between 10-year ASCVD risk and sudden death both overall and by sex. Odds ratios for males and females were compared in a pairwise fashion using an adjusted Wald test. Results: The average 10-year ASCVD risk was higher among sudden death victims compared to living controls for both males (36.4 ± 22.2 vs. 16.3 ± 16.0, p-value &lt;0.001) and females (20.6 ± 17.9 vs. 7.1 ± 8.4, p-value &lt;0.001). Among intermediate or high 10-year ASCVD risk sudden death victims and controls, aspirin and statin use were low (13-21%). Among those with intermediate or high ASCVD risk, male sudden death victims were less likely than living controls to be prescribed aspirin (p-value 0.007). Comparing sudden death victims to living controls, there was no difference in statin use among males or in aspirin or statin use among females. There was no significant difference in the strength of association between 10-year ASCVD risk categories and sudden death by sex. Conclusions: Although the average 10-year ASCVD risk of sudden death victims is higher than living controls both overall and by sex, the use of aspirin and statin was low and did not differ significantly between victims and controls. Improvements are needed to increase the use of guideline-based preventive medications.
Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study
Authors: Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, Geralyn Gilotti, Wendy Y. Cheng, Chi Gao, Mu Cheng, Melody Wu, Mei Sheng Duh, Claire N. Harrison
Journal: Blood (2021)
A Method to Measure Voxelotor Exposure in People with Sickle Cell Disease Using Capillary Zone Electrophoresis
Authors: Susanna A Curtis, Elana M Friedman, Caterina Minniti, Annie Ngyuen Dang, Mira Pochron, Merin Thomas, Jaime Luis Betancourt, Leena Vattappally, Andrew Crouch, Julissa Morales, Sean Campbell
Journal: Blood (2021)
Advances in systemic therapy for non-small cell lung cancer
Authors: Meagan Miller, Nasser Hanna
Journal: BMJ (2021)

ABSTRACT Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.
A Novel Protocol for Rituximab Administration with Reduced Incidence of Severe Infusion-Related Adverse Reactions in Patients with B-Cell Non-Hodgkin Lymphoma
Authors: Daisuke Tsutsumi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Shinya Tsuboi, Isamu Odagiri, Takashi Yamauchi, Susumu Ootsuka, Yoshihiro Hatta, Yukinaga Kishikawa
Journal: Blood (2021)
Cohesion mechanisms for bioadhesives
Authors: Yazhong Bu, Abhay Pandit
Journal: Bioactive Materials (2021)

Due to the nature of non-invasive wound closure, the ability to close different forms of leaks, and the potential to immobilize various devices, bioadhesives are altering clinical practices. As one of the vital factors, bioadhesives' strength is determined by adhesion and cohesion mechanisms. As well as being essential for adhesion strength, the cohesion mechanism also influences their bulk functions and the way the adhesives can be applied. Although there are many published reports on various adhesion mechanisms, cohesion mechanisms have rarely been addressed. In this review, we have summarized the most used cohesion mechanisms. Furthermore, the relationship of cohesion strategies and adhesion strategies has been discussed, including employing the same functional groups harnessed for adhesion, using combinational approaches, and exploiting different strategies for cohesion mechanism. By providing a comprehensive insight into cohesion strategies, the paper has been integrated to offer a roadmap to facilitate the commercialization of bioadhesives.
The Effect of Individualized Pain Plans for Patients with Sickle Cell Disease on Emergency Provider Satisfaction: A Win for the Patient Can be a Win for the Provider
Authors: Sherraine Della-Moretta, Rui Li, David Way, Michael G (MD) Purcell, Melanie Heinlein, Eric Adkins, Luca Delatore, Payal Desai, Ying Huang
Journal: Blood (2021)
Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice
Authors: Suheda Erener, Cara E. Ellis, Adam Ramzy, Maria M. Glavas, Shannon O’Dwyer, Sandra Pereira, Tom Wang, Janice Pang, Jennifer E. Bruin, Michael J. Riedel, Robert K. Baker, Travis D. Webber, Marina Lesina, Matthias Blüher, Hana Algül, Janel L. Kopp, Stephan Herzig, Timothy J. Kieffer
Journal: Cell Reports Medicine (2021)
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Authors: Tomiko Oskotsky, Ivana Marić, Alice Tang, Boris Oskotsky, Ronald J. Wong, Nima Aghaeepour, Marina Sirota, David K. Stevenson
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Antidepressant use may be associated with reduced levels of several proinflammatory cytokines suggested to be involved with the development of severe COVID-19. An association between the use of selective serotonin reuptake inhibitors (SSRIs)—specifically fluoxetine hydrochloride and fluvoxamine maleate—with decreased mortality among patients with COVID-19 has been reported in recent studies; however, these studies had limited power due to their small size. <h3>Objective</h3> To investigate the association of SSRIs with outcomes in patients with COVID-19 by analyzing electronic health records (EHRs). <h3>Design, Setting, and Participants</h3> This retrospective cohort study used propensity score matching by demographic characteristics, comorbidities, and medication indication to compare SSRI-treated patients with matched control patients not treated with SSRIs within a large EHR database representing a diverse population of 83 584 patients diagnosed with COVID-19 from January to September 2020 and with a duration of follow-up of as long as 8 months in 87 health care centers across the US. <h3>Exposures</h3> Selective serotonin reuptake inhibitors and specifically (1) fluoxetine, (2) fluoxetine or fluvoxamine, and (3) other SSRIs (ie, not fluoxetine or fluvoxamine). <h3>Main Outcomes and Measures</h3> Death. <h3>Results</h3> A total of 3401 adult patients with COVID-19 prescribed SSRIs (2033 women [59.8%]; mean [SD] age, 63.8 [18.1] years) were identified, with 470 receiving fluoxetine only (280 women [59.6%]; mean [SD] age, 58.5 [18.1] years), 481 receiving fluoxetine or fluvoxamine (285 women [59.3%]; mean [SD] age, 58.7 [18.0] years), and 2898 receiving other SSRIs (1733 women [59.8%]; mean [SD] age, 64.7 [18.0] years) within a defined time frame. When compared with matched untreated control patients, relative risk (RR) of mortality was reduced among patients prescribed any SSRI (497 of 3401 [14.6%] vs 1130 of 6802 [16.6%]; RR, 0.92 [95% CI, 0.85-0.99]; adjusted<i>P</i> = .03); fluoxetine (46 of 470 [9.8%] vs 937 of 7050 [13.3%]; RR, 0.72 [95% CI, 0.54-0.97]; adjusted<i>P</i> = .03); and fluoxetine or fluvoxamine (48 of 481 [10.0%] vs 956 of 7215 [13.3%]; RR, 0.74 [95% CI, 0.55-0.99]; adjusted<i>P</i> = .04). The association between receiving any SSRI that is not fluoxetine or fluvoxamine and risk of death was not statistically significant (447 of 2898 [15.4%] vs 1474 of 8694 [17.0%]; RR, 0.92 [95% CI, 0.84-1.00]; adjusted<i>P</i> = .06). <h3>Conclusions and Relevance</h3> These results support evidence that SSRIs may be associated with reduced severity of COVID-19 reflected in the reduced RR of mortality. Further research and randomized clinical trials are needed to elucidate the effect of SSRIs generally, or more specifically of fluoxetine and fluvoxamine, on the severity of COVID-19 outcomes.
Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial
Authors: Zoe Craig, Christopher Parrish, Charlotte Pawlyn, Martin F. Kaiser, Catherine Olivier, John R Jones, Mark T Drayson, Roger G Owen, Matthew W Jenner, Gordon Cook, Walter Martin Gregory, Faith E Davies, Gareth J. Morgan, Graham Jackson, David Cairns
Journal: Blood (2021)
Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)
Authors: John F. Tisdale, Alexis A. Thompson, Markus Y. Mapara, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Banu Aygun, Kimberly A. Kasow, Stacey Rifkin-Zenenberg, Manfred Schmidt, Francis J. Pierciey, Dustin Whitney, Cynthia Rogers, Mauris Nnamani, Marianna Foos, Alex Miller, Xinyan Zhang, Jessie Lynch, Mark C. Walters, Julie Kanter, Melissa Bonner
Journal: Blood (2021)
A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse
Authors: Andrew F. Berdel, Christoph Rollig, Martin Wermke, Linus Angenendt, Leo Ruhnke, Jan-Henrik Mikesch, Teresa Hemmerle, Klaus Wethmar, Torsten Kessler, Mirjam Gerwing, Daniel Hescheler, Michael Schäfers, Wolfgang Hartmann, Bianca Altvater, Claudia Rossig, Georg Lenz, Matthias Stelljes, Bjoern Rueter, Dario Neri, Wolfgang E. Berdel, Christoph Schliemann
Journal: Blood (2021)
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Authors: Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N. Smith, Archana Balan, James R. White, Christopher Cherry, I. K. Ashok Sivakumar, Xiaoshan M. Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B. Illei, Drew M. Pardoll, Rachel Karchin, Victor E. Velculescu, Julie R. Brahmer, Suresh S. Ramalingam
Journal: Nature Medicine (2021)

Abstract Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial ( NCT02899195 ) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control with cisplatin and pemetrexed chemotherapy; secondary and exploratory endpoints included safety, progression-free survival and biomarkers of response. The combination of durvalumab with chemotherapy met the pre-specified primary endpoint, reaching a median survival of 20.4 months versus 12.1 months with historical control. Treatment-emergent adverse events were consistent with known side effects of chemotherapy, and all adverse events due to immunotherapy were grade 2 or lower. Integrated genomic and immune cell repertoire analyses revealed that a higher immunogenic mutation burden coupled with a more diverse T cell repertoire was linked to favorable clinical outcome. Structural genome-wide analyses showed a higher degree of genomic instability in responding tumors of epithelioid histology. Patients with germline alterations in cancer predisposing genes, especially those involved in DNA repair, were more likely to achieve long-term survival. Our findings indicate that concurrent durvalumab with platinum-based chemotherapy has promising clinical activity and that responses are driven by the complex genomic background of malignant pleural mesothelioma.
Evaluating the Impact of Therapy Related Healthcare Team Burden on Selection of Novel Therapies for Chronic Lymphocytic Leukemia and Lymphoid Malignancies
Authors: Maishara Muquith, Heather Reves, Gurbakhash Kaur, Yazan F. Madanat, Praveen Ramakrishnan Geethakumari, Ankit Kansagra, Prapti Patel, Larry D. Anderson, Madhuri Vusirikala, Robert H. Collins, Farrukh T. Awan
Journal: Blood (2021)
Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?
Authors: Giovanni Caocci, Olga Mulas, Daniela Mantovani, Alessandro Costa, Andrea Galizia, Luca Barabino, Marianna Greco, Roberta Murru, Giorgio La Nasa
Journal: Blood (2021)
Abstract 10002: Risk Factors and Clinical Outcomes of Non-Home Discharge in Patients with Acute Decompensated Heart Failure: An Observational Study
Authors: Koichi Washida, Takao Kato, Neiko Ozasa, Takeshi Morimoto, Hidenori Yaku, Yuta Seko, Erika Yamamoto, Yusuke Yoshikawa, Yugo Yamashita, Takeshi Kimura
Journal: Circulation (2021)

Background: No clinical studies have focused on the factors associated with discharge destination in patients with acute decompensated heart failure. Methods and Results: Of 4,056 consecutive patients hospitalized for ADHF in the KCHF registry, we analyzed 3,460 patients hospitalized from their homes and discharged alive. There were 3009 and 451 patients who were discharged to home (home discharge) and non-home (non-home discharge), respectively. We investigated the factors associated with non-home discharge and compared the outcomes between home discharge and non-home discharge. Factors independently and positively associated with non-home discharge were age ≥80 years (odds ratio [OR]:1.76, 95% confidence interval [CI]:1.28-2.42), body mass index ≤22 kg/m 2 (OR:1.49, 95%CI:1.12-1.97), poor medication adherence (OR:2.08,95%CI:1.49-2.88), worsening heart failure (OR:2.02, 95%CI:1.46-2.82), stroke during hospitalization (OR:3.74, 95%CI:1.75-8.00), functional decline (OR:12.24, 95%CI:8.74-17.14) and length of hospital stay &gt;16 days (OR:4.14, 95%CI:3.01-5.69), while those negatively associated were diabetes mellitus (OR:0.69, 95%CI:0.51-0.94), cohabitants (OR:0.62, 95%CI:0.46-0.85), and ambulatory state before admission (OR:0.25, 95%CI:0.18-0.36). The cumulative 1-year incidence of all-cause death was significantly higher in the non-home discharge group than in the home discharge group. The non-home discharge group compared with the home discharge group was associated with a higher adjusted risk for all-cause death (HR:1.66, P &lt;0.001). Conclusions: The discharge destination of acute decompensated heart failure patients is influenced by factors such as pre-hospital social background, age, body mass index, low self-care ability, events during hospitalization (worsening heart failure, stroke, etc.), functional decline, and length of hospital stay; moreover, the prognosis of non-home discharge patients is worse than that of home discharge patients.
Biological and Classical Prognostic Factors with Impact on Overall Survival in Patients with Early Stage (I/II) Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Authors: Luis Villela, Brady E. Beltrán, Denisse Castro, Ana Florencia Ramirez-Ibarguen, Marialejandra Alejandra Torres Viera, Guilherme Fleury Perini, Carmen Lome, Myrna Candelaria, Henry Idrobo, Sally Rose Paredes, Alana Von Glasenapp, Fabiola Valvert, Victoria Otero, Camila Peña, Lorena Fiad, Carlos Best, Rosa Oliday Rios, Humberto Martinez-Cordero, Melani Otañez, Fernando Pérez-Jacobo, Juan Ospina Idarraga, Rosio Baena, Cristaldo Nancy, Ana Carolina Oliver, María Victoria Irigoín, Larissa Lane Cardoso, Yusaima Rodriguez, Jose Macias, Maria Virginia Prates, Maria Alejandra Luna, Maria Elena Cabrera, Macarena Roa, Claudia Gajardo, Catalina Díaz, Efreen H Montano Figueroa, Erick Bichara, Karen Lilian Bonfil, Vera Larissa Cordero-Moreno, Bryan Valcarcel, Jorge J. Castillo, Luis Malpica Castillo
Journal: Blood (2021)
Pharmacist Integration into the Hemophilia Treatment Centre: A Canadian Pilot Project to Optimize Treatment and Improve Cost-Savings Using Pharmacokinetic Assessments of Hemophilia Patients
Authors: Nisha S Varughese, Alex Wong, Robert J Klaassen, Elaine W. Leung, Kathryn Elizabeth Webert, Sylvain Grenier, Sarah Jennings, Utsav Patel, Caitlin Jones, Simmi Sidhu, Regis Vaillancourt
Journal: Blood (2021)
Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis
Authors: Qi Wang, Bixi Tang, Dandan Sun, Ying Dong, Yinchun Ji, Huanyu Shi, Liwei Zhou, Yueyue Yang, Menglan Luo, Qian Tan, Lin Chen, Yue Dong, Cong Li, Rongrong Xie, Yi Zang, Jingkang Shen, Bing Xiong, Jia Li, Danqi Chen
Journal: Acta Pharmaceutica Sinica B (2021)

Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease with a median survival time of 3-5 years. Inaccurate diagnosis, limited clinical therapy and high mortality together indicate that the development of effective therapeutics for IPF is an urgent need. In recent years, it was reported that DDRs are potential targets in anti-fibrosis treatment. Based on previous work we carried out further structure modifications and led to a more selective inhibitor 47 by averting some fibrosis-unrelated kinases, such as RET, AXL and ALK. Extensive profiling of compound 47 has demonstrated that it has potent DDR1/2 inhibitory activities, low toxicity, good pharmacokinetic properties and reliable in vivo anti-fibrosis efficacy. Therefore, we confirmed that discoidin domain receptors are promising drug targets for IPF, and compound 47 would be a promising candidate for further drug development.
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Authors: Mehmet A. Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albiges, Lance C. Pagliaro, Eric G. Voog, Elaine T. Lam, Nikolay Kislov, Bradley A. McGregor, Aly-Khan A. Lalani, Bo Huang, Alessandra di Pietro, Stan Krulewicz, Paul B. Robbins, Toni K. Choueiri
Journal: Clinical Cancer Research (2021)

To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib.
64 A cloning and expression system of the neoantigen-specific TCRs from tumor-infiltrating lymphocytes by single-cell sequencing of paired TCRα and TCRβ chains
Authors: Yukari Kobayashi, Koji Nagaoka, Kaori Kubo, Toshikazu Nishie, Sachiko Okamoto, Tatsuji Enoki, Junichi Mineno, Yasuyoshi Sato, Shunji Takahashi, Jun Nakajima, Kazuhiro Kakimi
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background T-cells that target tumor neoantigens arising from cancer mutations are the primary mediators of cancer immunotherapies. Identifying neoantigens and T-cells that recognize them is essential for T-cell-based immunotherapy. However, neoantigen-reactive Tumor-infiltrating lymphocytes (TILs) are highly differentiated or exhausted with a limited proliferative capacity; it is challenging to expand them for a sufficient number to probe their specificity. Therefore, we developed a novel cloning and expression system to examine TCRs discovered by single-cell sequencing of TILs for their neoantigen-specificity. Methods TILs of lung cancer and sarcoma were analyzed. Surgically removed tumors were divided into several pieces. They were enzymatically digested to prepare fresh tumor digest (FTD) and cryopreserved. They were used to generate TIL cultures and perform WES and RNA-Seq to identify tumor-specific mutations. MHCflurry was used to predict the binding affinity of potential epitopes arising from these mutations to HLA class I. Peptides that were predicted to bind to patients‘ own MHC class I molecules strongly were then synthesized. Single TILs isolated with the ICELL8® cx system (Takara Bio) were dispensed into a nanowell TCR chip containing preprinted barcodes. Barcoded cDNAs were PCR-amplified in-chip, pooled off-chip, and used as a template in the TCR-specific PCR or for the whole transcriptome library generation of 5’ ends of all transcripts. Based on single-cell transcriptome data and TCR profiles of TILs, we predict and prioritize neoantigen-specific TCRs and cloned them into siTCR® retrovirus vectors. These TCRs were transduced into SUP-T1-based reporter cells in which ZsGreen fluorescent protein expression is controlled by AP-1 and NFAT binding sites. TCR-expressing reporter cells were cocultured with patient autologous APCs pulsed with a pool of candidate neoantigen peptides. ZsGreen expression indicates that TCRs match their cognate neoantigens. Results In a lung cancer patient, we set up 18 TIL cultures and obtained 12 TILs. TILs were cocultured with FTD; IFN-γ production was measured by ELISA to evaluate their reactivity to the autologous tumor. NGS identified 197 somatic mutations, 4 fusion genes, and 8 highly expressed cancer-testis antigens. Among them, 339 candidate peptides were synthesized and screened. In addition, we cloned 3 pairs of TCRαβ chains from most expanded TIL cultures and 4 TCRs from ex vivo TILs with exhausted phenotype. Two reporter cells that express TCRs from exhausted TILs responded to the same neoantigen peptide. Conclusions Generating TCR expressing cell lines facilitated the identifying neoantigens and their cognate TCR sequences from patients. Ethics Approval G3545
Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy
Authors: Saurabh Dahiya, Tim Luetkens, Stephanie Avila, Saurabh Dahiya, Philip Margiotta, Kim Hankey, Patricia Lesho, Sherri Bauman, Nancy Smith, Kathleen Ruehle, Seung-Tae Lee, Jennie Y. Law, John Baddley, Mehmet Hakan Kocoglu, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Djordje Atanackovic
Journal: Blood (2021)